查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965338

肺癌手術市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭對手分類，2021-2031年

Lung Cancer Surgery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Thoracotomy, Minimally Invasive Surgeries), By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺癌手術市場預計將從 2025 年的 67.2 億美元成長到 2031 年的 91.9 億美元，複合年成長率為 5.36%。

該市場涵蓋切除術、楔形切除術和全肺切除術等專業外科手術，並且擴大採用微創技術，例如胸腔鏡輔助手術 (VATS) 和機器人輔助系統來切除惡性腫瘤。推動市場成長的主要因素是全球肺癌發生率的上升以及早期篩檢計畫的擴展，這些計畫能夠發現更多早期可手術治療的病例。例如，美國癌症協會估計，到 2025 年，美國將新增 226,650 例肺癌病例，凸顯了對有效治療方法的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 67.2億美元
市場規模：2031年 91.9億美元
複合年成長率：2026-2031年 5.36%
成長最快的細分市場 節段切除術
最大的市場 北美洲

儘管存在這些積極趨勢，但市場仍面臨許多挑戰。肺癌確診時多晚期，意味著許多患者無法接受根治性手術。由於手術切除主要針對局部病灶，而肺癌通常在晚期轉移階段才被發現，因此適合接受此類治療方法的患者群體十分有限。由此，診斷延遲顯著阻礙了手術數量的成長，並限制了全球市場的潛力。

市場促進因素

機器人輔助胸腔鏡手術 (RATS) 的快速普及正在改變外科手術格局，其精準度遠超傳統開放手術和標準視訊輔助手術方法。外科醫生擴大使用機器人平台進行複雜的切除術和部分肺切除術，利用卓越的 3D 高清可視化技術和精密的器械操控，縮短住院時間，加快術後復健。這項技術進步正顯著推動手術數量的成長，尤其是在國際地區，為滿足臨床需求，RATS 的應用正在加速發展。在 2024 年 10 月舉行的 2024 年第三季財報電話會議上，Intuitive Surgical 報告稱，其在美國以外地區的手術量同比成長 24%，並指出胸腔外科手術和普通外科手術是推動這一成長的主要動力。

同時，非小細胞肺癌（NSCLC）在全球的發生率不斷上升，成為影響市場的重要人口因素，持續推高了根治性手術的需求。鑑於肺癌在全球癌症統計數據中仍佔據重要地位，醫療基礎設施面臨越來越大的壓力，需要加強其可切除腫瘤的手術能力。世界衛生組織（WHO）國際癌症研究機構（IARC）在2024年2月發布的《2022年全球癌症負擔報告》中指出，肺癌仍是全球最常見的癌症，每年新增病例約250萬例。然而，有效的早期檢測對於將這些病例轉化為實際的手術治療至關重要。正如美國肺臟協會（ALA）2024年的調查顯示，美國祇有16%的人接受了建議的篩檢。縮小這一巨大差距將大幅增加符合挽救生命手術條件的患者人數。

市場挑戰

市場面臨的核心挑戰之一是晚期診斷的普遍存在，這嚴重限制了符合根治性手術治療條件的患者數量。切除術和全肺切除術等外科手術主要針對腫瘤局限於肺部的早期局限性病變。當惡性腫瘤在晚期或轉移階段被發現時，治療通訊協定通常會從手術切除轉向化療和免疫療法等全身性治療。這種生物學上的限制明確界定了市場規模的上限，因為大多數新患者在初次診斷時並不適合手術。

診斷延誤會降低手術量與疾病總數的比率，直接削弱市場收入潛力。根據美國肺臟協會2024年的數據，美國約有43%的肺癌病例在確診時已晚期，此時存活率急劇下降，根治性手術幾乎不再可行。這項統計數據凸顯了癌症發生率上升與外科手術市場成長之間的脫節。儘管發病率不斷上升，但手術器械和機器人手術市場仍然受到限制，因為近一半的患者需要的是非手術安寧療護而非手術干預。

市場趨勢

將輔助性治療和手術全期免疫療法整合到手術通訊協定中，從根本上改變了可切除非小細胞肺癌（NSCLC）的診斷標準。透過在切除前後使用免疫查核點抑制劑，外科醫生可以降低腫瘤分期並清除微轉移灶，從而擴大符合根治性治療條件的患者群體，並改善長期預後。這項通訊協定的改變得到了近期臨床研究的支持，這些研究表明，與化療和手術相比，全身性治療聯合手術可顯著提高無惡化存活期。例如，Oncology News Central 於 2025 年 6 月報道，在 CheckMate 77T 試驗的最新分析中，手術全期手術期使用納Nivolumab治療顯著改善了臨床結局，治療組的風險比為 0.61（與安慰劑組相比）。

同時，保留肺實質的部分肺葉切除術日益受到青睞，這正在革新早期肺結節的治療。治療重點正從傳統的切除術轉向最大限度地保留肺功能。對於較小的周邊型腫瘤，這種策略正被擴大採用，因為切除術可以在達到與傳統肺葉切除術相當的腫瘤控制效果的同時，降低術後呼吸系統併發症的風險，並提高患者的生活品質。真實世界的生存數據支持了這種組織保留手術的臨床有效性。在2025年1月的新聞稿中，日本胸腔外科醫師協會強調，切除術的五年存活率達到了69.6%，這鞏固了其作為早期患者與傳統切除術同樣有效的替代方案的地位。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肺癌手術市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（開胸手術（切除術、袖式切除術、部分切除術、全肺切除術）、微創手術）
    • 依最終使用者（醫院、門診手術中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肺癌手術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肺癌手術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肺癌手術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肺癌手術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肺癌手術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肺癌手術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Intuitive Surgical
  • Medtronic
  • Ethicon
  • Stryker
  • Karl Storz
  • Olympus
  • Richard Wolf
  • Microsurgical Systems
  • ConMed
  • Zimmer Biomet

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25306

The Global Lung Cancer Surgery Market is projected to expand from USD 6.72 Billion in 2025 to USD 9.19 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.36%. This market encompasses specialized surgical interventions such as lobectomy, wedge resection, and pneumonectomy, which are increasingly executed through minimally invasive methods like Video-Assisted Thoracic Surgery (VATS) and robotic-assisted systems to excise malignant tumors. Growth is primarily propelled by the escalating global incidence of lung malignancies alongside the broadening of early screening programs, which effectively detect a greater volume of operable, early-stage cases. For instance, the American Cancer Society estimated that there were 226,650 new lung cancer cases in the United States in 2025, highlighting the urgent and ongoing need for effective therapeutic procedures.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.72 Billion
Market Size 2031USD 9.19 Billion
CAGR 2026-20315.36%
Fastest Growing SegmentSegmentectomy
Largest MarketNorth America

Despite these favorable trends, the market encounters a substantial hurdle due to the high frequency of late-stage diagnoses, which disqualifies a significant segment of patients from curative surgery. Because surgical resection is largely intended for localized disease, the common detection of lung cancer at advanced metastatic stages severely restricts the population suitable for these interventions. Consequently, delays in diagnosis serve as a major restraint on the growth of surgical case volumes and limit the overall potential of the market on a global scale.

Market Driver

The swift integration of Robot-Assisted Thoracic Surgery (RATS) is transforming the procedural environment by delivering precision that exceeds traditional open thoracotomy and standard video-assisted methods. Surgeons are increasingly deploying robotic platforms for intricate lobectomies and segmentectomies, taking advantage of superior 3D high-definition visualization and refined instrument dexterity, which contribute to shorter hospital stays and faster postoperative recovery. This technological evolution is fueling significant volume increases, especially in international regions where adoption is quickening to address clinical needs; Intuitive Surgical reported in their October 2024 'Q3 2024 Earnings Call' that procedure volumes outside the United States surged by 24% year-over-year, with thoracic procedures specifically identified as a robust driver of this growth alongside general surgery.

Concurrently, the increasing global prevalence of Non-Small Cell Lung Cancer (NSCLC) acts as the central demographic force behind the market, generating continuous demand for curative surgical options. As lung cancer remains a dominant figure in global oncology statistics, healthcare infrastructures face mounting pressure to bolster surgical capabilities for resectable tumors; the World Health Organization International Agency for Research on Cancer noted in its February 2024 'Global Cancer Burden 2022' release that lung cancer continued to be the most frequently diagnosed cancer globally, representing roughly 2.5 million new cases. However, transforming this incidence into surgical volume depends heavily on effective early detection efforts, as evidenced by the American Lung Association's 2024 finding that only 16% of eligible candidates in the United States participated in recommended screening, highlighting a vast gap that, if addressed, would substantially elevate the number of patients qualifying for life-saving resections.

Market Challenge

The central obstacle facing the market is the widespread prevalence of late-stage diagnoses, which severely limits the number of patients eligible for curative surgical treatments. Procedures such as lobectomy and pneumonectomy are primarily designated for localized, early-stage disease where the tumor remains confined to the lung. Once a malignancy is identified at an advanced or metastatic stage, treatment protocols generally transition from surgical resection to systemic therapies like chemotherapy or immunotherapy, creating a biological constraint that places a hard ceiling on addressable market volume by rendering a large portion of the incident population medically unsuitable for surgery at the time of initial diagnosis.

This delay in diagnosis directly undermines market revenue potential by lowering the ratio of performed procedures to total disease incidence. According to data from the American Lung Association in 2024, roughly 43% of lung cancer cases in the United States were detected at a late stage, a phase where survival rates decline sharply and curative surgery is seldom a viable option. This statistic highlights a discrepancy between escalating cancer rates and surgical market growth; even as incidence figures rise, the market for surgical devices and robotics remains constrained because nearly half of the patient population requires non-surgical palliative care rather than operative interventions.

Market Trends

The integration of neoadjuvant and perioperative immunotherapy into surgical protocols is fundamentally altering resectability standards for non-small cell lung cancer (NSCLC). By utilizing immune checkpoint inhibitors both before and after resection, surgeons can downstage tumors and eradicate micrometastases, thereby broadening the pool of candidates for curative outcomes and enhancing long-term prognoses. This shift in protocol is bolstered by recent clinical findings showing that combining systemic therapy with surgery produces superior event-free survival compared to chemotherapy and surgery alone; for instance, Oncology News Central reported in June 2025 that an updated analysis of the CheckMate 77T trial indicated the perioperative nivolumab regimen significantly improved clinical results, achieving a hazard ratio of 0.61 in favor of the treatment group over the placebo.

Simultaneously, a growing preference for parenchyma-sparing segmentectomy is revolutionizing the management of early-stage pulmonary nodules, shifting focus away from traditional lobectomy to maximize lung function preservation. This strategy is increasingly selected for small, peripheral tumors where sub-lobar resection provides equivalent oncological control while reducing the risk of postoperative respiratory morbidity and improving patient quality of life. The clinical validity of this tissue-preserving method is supported by real-world survival data; the Society of Thoracic Surgeons highlighted in a January 2025 press release that segmentectomy achieved a 5-year overall survival rate of 69.6%, confirming its status as a comparable and effective alternative to lobectomy for appropriate early-stage patients.

Key Market Players

  • Intuitive Surgical
  • Medtronic
  • Ethicon
  • Stryker
  • Karl Storz
  • Olympus
  • Richard Wolf
  • Microsurgical Systems
  • ConMed
  • Zimmer Biomet

Report Scope

In this report, the Global Lung Cancer Surgery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Surgery Market, By Type

  • Thoracotomy (Lobectomy, Sleeve Resection, Segmentectomy, Pneumonectomy)
  • Minimally Invasive Surgeries

Lung Cancer Surgery Market, By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Lung Cancer Surgery Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Surgery Market.

Available Customizations:

Global Lung Cancer Surgery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Surgery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Thoracotomy (Lobectomy, Sleeve Resection, Segmentectomy, Pneumonectomy), Minimally Invasive Surgeries)
    • 5.2.2. By End User (Hospitals, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Lung Cancer Surgery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lung Cancer Surgery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Lung Cancer Surgery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Lung Cancer Surgery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User

7. Europe Lung Cancer Surgery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lung Cancer Surgery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Lung Cancer Surgery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Lung Cancer Surgery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Lung Cancer Surgery Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Lung Cancer Surgery Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Lung Cancer Surgery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Lung Cancer Surgery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Lung Cancer Surgery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Lung Cancer Surgery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Lung Cancer Surgery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Lung Cancer Surgery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Lung Cancer Surgery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Lung Cancer Surgery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Lung Cancer Surgery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Lung Cancer Surgery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. South America Lung Cancer Surgery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lung Cancer Surgery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Lung Cancer Surgery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Lung Cancer Surgery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Lung Cancer Surgery Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Intuitive Surgical
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Medtronic
  • 15.3. Ethicon
  • 15.4. Stryker
  • 15.5. Karl Storz
  • 15.6. Olympus
  • 15.7. Richard Wolf
  • 15.8. Microsurgical Systems
  • 15.9. ConMed
  • 15.10. Zimmer Biomet

16. Strategic Recommendations

17. About Us & Disclaimer